Aston Particle Technologies

Executive Summary

Aston Particle Technologies (APT) is a UK-based biotech company specializing in dry particle coating for pharmaceutical APIs. Its patented low-shear isothermal dry particle coating (iDPC) technology enables precise layering without heat or solvents, preserving sensitive biomolecules and improving formulation stability. APT offers integrated R&D, characterization, and scalable manufacturing services targeting inhalational, biological, and oral solid dose medicines. Founded in 2018, the company is currently at Phase 1/2 stage and focuses on addressing stability and bioavailability challenges through its innovative coating platform. With a growing interest in non-invasive drug delivery and biologics formulation, APT is well-positioned to partner with pharmaceutical companies seeking enhanced drug performance. The company's service-based business model allows it to generate near-term revenue while advancing its own pipeline. Key advantages include reduced degradation, improved flow properties, and compatibility with heat- or solvent-sensitive APIs. As the pharmaceutical industry increasingly adopts continuous manufacturing and personalized medicine, APT's technology offers a versatile solution for both small molecules and biologics.

Upcoming Catalysts (preview)

• H2 2026Partnership with major pharma for inhalation formulation services70% success
• Q3 2026Series A funding round to scale manufacturing capacity60% success
• Q4 2026Publication of proof-of-concept data for biologic dry powder formulations80% success